San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Cellics Therapeutics is raising $25,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jie Zhang played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cellics Therapeutics
Cellics Therapeutics, Inc. (Cellics) was founded in 2014 by UC San Diego professor Liangfang Zhang based on his award-winning Cellular Nanosponge Technology. Cellics was created with the goal of applying the Cellular Nanosponge Technology to treat and prevent diseases. The mission of Cellics is to employ innovative biomimetic nanomedicines to address serious diseases with a high unmet medical need. The companys initial primary focus is on autoimmune and inflammatory diseases and hard-to-treat infectious diseases. Additionally, Cellics is seeking to develop best-in-class vaccines for various diseases. The company is currently on schedule to advance its lead product candidate CTI-005 to human clinical trials for the treatment of bacterial pneumonia. It is the passion and goal of Cellics to use advanced technology to help human beings live healthier and longer lives.

To learn more about Cellics Therapeutics, visit http://cellics.com/

Contact:
Jie Zhang, Chief Executive Officer
858-412-6148
jzhang@cellics.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved